Alpha B-crystallin-a validated prognostic factor for poor prognosis in squamous cell carcinoma of the oral cavity

Annertz, Karin, Enoksson, Jens, Williams, Rebecca, Jacobsson, Helene, Coman, William B. and Wennerberg, Johan (2014) Alpha B-crystallin-a validated prognostic factor for poor prognosis in squamous cell carcinoma of the oral cavity. Acta Oto-Laryngologica, 134 5: 543-550. doi:10.3109/00016489.2013.872293

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Annertz, Karin
Enoksson, Jens
Williams, Rebecca
Jacobsson, Helene
Coman, William B.
Wennerberg, Johan
Title Alpha B-crystallin-a validated prognostic factor for poor prognosis in squamous cell carcinoma of the oral cavity
Journal name Acta Oto-Laryngologica   Check publisher's open access policy
ISSN 1651-2251
Publication date 2014-05-01
Year available 2014
Sub-type Article (original research)
DOI 10.3109/00016489.2013.872293
Open Access Status Not Open Access
Volume 134
Issue 5
Start page 543
End page 550
Total pages 8
Place of publication London, United Kingdom
Publisher Informa Healthcare
Language eng
Formatted abstract
Alpha B-crystallin was found to be an independent prognostic marker for poor prognosis in oral cavity tumours. For oropharyngeal cancer, alpha B-crystallin had no prognostic value.


The aim of this study was to see if earlier findings of alpha B-crystallin as an independent prognostic marker, and SPARC/osteonectin, PAI-1 and uPA as a prognostic combination for poor outcome in squamous cell carcinoma (SCC) of the head and neck could be confirmed in a new set of tumours.

In a consecutive series of patients, assessed and primarily treated at a tertiary referral centre, histological sections from 55 patients with oral and SCC (OOPHSSC) with complete clinical data and follow-up were obtained. Oral and oropharyngeal tumours were studied separately. Immunohistochemical detection of alpha B-crystallin, SPARC/osteonectin, PAI-1 and uPA expression was performed.

Thirty-five patients had an oral tumour and 20 patients an oropharyngeal tumour. Twenty-five oral tumours stained negatively and 10 positively for alpha B-crystallin. For oropharyngeal tumours the figures were 15 negatively and 5 positively. Median disease-specific survival (DSS) for both sites was 33.8 and 11.9 months, for negative and positive alpha B-crystallin staining, respectively (p = 0.046). For the oral cavity, median DSS was 27.3 months for negative tumours and 7.5 months for positive tumours (p = 0.012). Corresponding figures for oropharyngeal tumours were 33.8 and 34.1 months (p = 0.95). Thus, significance in survival was only found in oral cavity tumours. In multivariate analyses there were no significant differences in DSS in the oropharyngeal group when adjusted for tumour size (T status) and presence of neck node metastasis (N status). In the oral cavity group, the significantly better DSS for negative tumours became even stronger when adjusted for T and N status. No statistical difference was found in DSS between positive and negative staining for SPARC/osteonectin, PAI-1 or uPA.
Keyword HNSCC
Oral cancer
Prognostic marker
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 06 May 2014, 12:13:48 EST by System User on behalf of School of Medicine